366 related articles for article (PubMed ID: 29661225)
21. EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer.
Wang G; He L; Wang S; Zhang M; Li Y; Liu Q; Sun N; Zhang X; Liu Y; Zhang J; Tai J; Ni X
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32459310
[TBL] [Abstract][Full Text] [Related]
22. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
Patera AC; Drewry AM; Chang K; Beiter ER; Osborne D; Hotchkiss RS
J Leukoc Biol; 2016 Dec; 100(6):1239-1254. PubMed ID: 27671246
[TBL] [Abstract][Full Text] [Related]
23. Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity.
Niedźwiedzka-Rystwej P; Majchrzak A; Aksak-Wąs B; Serwin K; Czajkowski Z; Grywalska E; Korona-Głowniak I; Roliński J; Parczewski M
Cells; 2022 Jun; 11(12):. PubMed ID: 35741107
[TBL] [Abstract][Full Text] [Related]
24. Soluble PD-L1 in blood correlates positively with neutrophil and negatively with lymphocyte mRNA markers and implies adverse sepsis outcome.
Derigs M; Heers H; Lingelbach S; Hofmann R; Hänze J
Immunol Res; 2022 Oct; 70(5):698-707. PubMed ID: 35732880
[TBL] [Abstract][Full Text] [Related]
25. Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.
Yan X; Gu Y; Wang C; Sun S; Wang X; Tian J; Wang M; Ji X; Duan X; Gao H; Fang Q; Dong W; Zhang X; Xue Q
Clin Immunol; 2019 Oct; 207():68-78. PubMed ID: 31374257
[TBL] [Abstract][Full Text] [Related]
26. The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides.
Grywalska E; Smarz-Widelska I; Krasowska-Zajac E; Korona-Glowniak I; Zaluska-Patel K; Mielnik M; Podgajna M; Malm A; Rolinski J; Zaluska W
Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):133-143. PubMed ID: 28770269
[TBL] [Abstract][Full Text] [Related]
27. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
[TBL] [Abstract][Full Text] [Related]
28. [Effects and molecular mechanism of histone methyltransferase enhancer of zeste homolog 2 on regulating sepsis-induced T cell dysfunction].
Li Z; Zhao D; Zhou X; Tang L
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Apr; 34(4):357-361. PubMed ID: 35692198
[TBL] [Abstract][Full Text] [Related]
29. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
30. Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma.
Inoue S; Horiuchi Y; Setoyama Y; Takeuchi Y; Beck Y; Murakami T; Odaka A
J Surg Res; 2020 Sep; 253():201-213. PubMed ID: 32380346
[TBL] [Abstract][Full Text] [Related]
31. Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B.
Zhang WJ; Peng CH; Zheng SS
Hepatobiliary Pancreat Dis Int; 2013 Aug; 12(4):394-9. PubMed ID: 23924497
[TBL] [Abstract][Full Text] [Related]
32. Clinical Significance of Dynamics of Programmed Death Ligand-1 Expression on Circulating CD14
Huang ZY; Xu P; Li JH; Zeng CH; Song HF; Chen H; Zhu YB; Song YY; Lu HL; Shen CP; Zhang XG; Wu MY; Wang XF
Viral Immunol; 2017 Apr; 30(3):224-231. PubMed ID: 28005469
[TBL] [Abstract][Full Text] [Related]
33. PD-L1
Zacca ER; Onofrio LI; Acosta CDV; Ferrero PV; Alonso SM; Ramello MC; Mussano E; Onetti L; Cadile II; Stancich MI; Taboada Bonfanti MC; Montes CL; Acosta Rodríguez EV; Gruppi A
Front Immunol; 2018; 9():2241. PubMed ID: 30327652
[No Abstract] [Full Text] [Related]
34. Integrin and PD-1 Ligand Expression on Circulating Extracellular Vesicles in Systemic Inflammatory Response Syndrome and Sepsis.
Kawamoto E; Masui-Ito A; Eguchi A; Soe ZY; Prajuabjinda O; Darkwah S; Park EJ; Imai H; Shimaoka M
Shock; 2019 Jul; 52(1):13-22. PubMed ID: 30036273
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1.
Bodhankar S; Chen Y; Vandenbark AA; Murphy SJ; Offner H
J Neuroinflammation; 2013 Sep; 10():111. PubMed ID: 24015822
[TBL] [Abstract][Full Text] [Related]
36. Checkpoint molecule expression by B and T cell lymphomas in dogs.
Hartley G; Elmslie R; Dow S; Guth A
Vet Comp Oncol; 2018 Sep; 16(3):352-360. PubMed ID: 29380929
[TBL] [Abstract][Full Text] [Related]
37. The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis.
Shen L; Shi H; Gao Y; Ou Q; Liu Q; Liu Y; Wu J; Zhang W; Fan L; Shao L
Tuberculosis (Edinb); 2016 Dec; 101():146-150. PubMed ID: 27865385
[TBL] [Abstract][Full Text] [Related]
38. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005
[TBL] [Abstract][Full Text] [Related]
39. PD-1, PD-L1 and PD-L2 Expression in Mantle Cell Lymphoma and Healthy Population.
Karolova J; Radek M; Helman K; Spacek M; Trneny M; Klener P
Folia Biol (Praha); 2020; 66(4):117-122. PubMed ID: 33745258
[TBL] [Abstract][Full Text] [Related]
40. PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?
Cantero-Cid R; Casas-Martin J; Hernández-Jiménez E; Cubillos-Zapata C; Varela-Serrano A; Avendaño-Ortiz J; Casarrubios M; Montalbán-Hernández K; Villacañas-Gil I; Guerra-Pastrián L; Peinado B; Marcano C; Aguirre LA; López-Collazo E
BMC Cancer; 2018 Oct; 18(1):945. PubMed ID: 30285662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
